![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Eli Lilly’s Lyumjev Wins FDA Approval for Use in Insulin Pumps
Eli Lilly’s Lyumjev Wins FDA Approval for Use in Insulin Pumps
![Eli Lilly logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Eli-Lilly-logo.gif?t=1616695830&width=430)
Eli Lilly’s injectable insulin Lyumjev has won an expanded FDA indication for continuous subcutaneous infusion using an insulin pump.
The approval was supported by a phase 3 study showing Lyumjev, a specific formulation of insulin lispro, when delivered via insulin pump in adults with type 1 diabetes, was noninferior to Lilly’s injectable insulin Humalog.
Lyumjev first received FDA approval in June 2020 to reduce blood sugar levels and accelerate insulin uptake following meals in adults with type 1 and 2 diabetes.
Upcoming Events
-
21Oct